Bifidobacterium longum transitional microorganisms, compositions and uses thereof
AssigneesThe Broad Institute, Inc., The General Hospital Corporation, Societe des Produits Nestle S.A.
InventorsRamnik Xavier, Hera Vlamakis, Tommi Vatanen, Olga Sakwinska, Léa Siegwald, Stéphane Duboux, Catherine Ngom-Bru
Life of this patent
Estimating the term…
Abstract
Described in several exemplary embodiments are Bifidobacterium longum subspecies, microorganisms and formulations thereof. Described in several exemplary embodiments are formulations, such as synthetic formulations, that contain one or more of the Bifidobacterium longum subspecies microorganisms. Described in several embodiments herein is use of the Bifidobacterium longum subspecies microorganisms and formulations thereof, such as in an infant and/or young child.
Claims32
A synthetic formulation comprising:
- one or more Bifidobacterium longum (B. longum) transitional clade microorganisms which has at least 98.6% Average Nucleotide Identity (ANI) with at least one strain selected in the group consisting of:
- CNCM I-5683, CNCM I-5684, CNCM I-5685, CNCM I-5686 and CNCM I-5687.
A synthetic formulation comprising one or more Bifidobacterium longum (B. longum) transitional clade microorganisms characterized by the presence of all genes from Table 2.
The synthetic formulation of claim 7, wherein the fat source is a milk derived fat source or equivalent thereof, wherein the protein source is a milk derived protein source or equivalent thereof, and/or wherein the carbohydrate source is a milk derived carbohydrate source or equivalent thereof.
A genetically modified microorganism or population thereof, wherein the genetically modified microorganism is not of a Bifidobacterium longum transitional clade and is genetically modified to comprise modified expression of one or more genes from Table 1.
A method for promoting/assisting transition from a milk-based diet to solid food and/or promoting gut microbiota adapted to metabolize both milk derived carbohydrates and fibers or a derivative thereof in an infant and/or young child comprising:
- administering, to the infant and/or young child, one or more Bifidobacterium longum (B. longum) transitional clade microorganism which has at least 98.6 Average Nucleotide Identify (ANI) with at least one strain selected in the group consisting of:
- CNCM I-5683, CNCM I-5684, CNCM I-5685, CNCM I-5686 and CNCM I-5687.
A method of identifying a gastrointestinal microbiome modulating agent comprising:
- administering an amount of a test agent to a subject;
- and
- determining a microbiome structure of a gastrointestinal tract of the subject by at least determining the relative abundance of one or more one or more Bifidobacterium longum (B. longum) microorganisms characterized by at least 98.6% Average Nucleotide identity (ANI) with at least one strain selected in the group consisting of:
- CNCM I-5683, CNCM I-5684, CNCM I-5685, CNCM I-5686 and CNCM I-5687,
- wherein the gastrointestinal microbiome modulating agent is effective to increase or decrease the relative abundance of one or more of the one or more B. longum microorganism characterized by the presence of the B. longum transitional clade genes.
A Bifidobacterium longum (B. longum) microorganism characterized by at least 98.6% Average Nucleotide identity (ANI) with at least one strain selected in the group consisting of:
- CNCM I-5683, CNCM I-5684, CNCM I-5685, CNCM I-5686 and CNCM I-5687, and combinations thereof.
A Bifidobacterium longum (B. longum) microorganism as in claim 25, wherein the B. longum microorganism is characterized by the presence of all genes from Table 1.
Dependencies are inferred from the claim text.